Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter

被引:10
|
作者
Shi, Hui [1 ,2 ,3 ]
Guo, Le-Hang [1 ,2 ,3 ]
Zhang, Yi-Feng [1 ,2 ,3 ]
Fu, Hui-Jun [2 ,3 ,4 ]
Zheng, Jia-Yi [2 ,3 ,4 ]
Wang, Han-Xiang [1 ,2 ,3 ]
Zhao, Chong-Ke [1 ,2 ,3 ]
Xu, Hui-Xiong [1 ,2 ,3 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Med Ultrasound,Canc Ctr,Ultrasound Res & Edu, Shanghai 200072, Peoples R China
[2] Tongji Univ, Sch Med, Thyroid Inst, Shanghai 200072, Peoples R China
[3] Shanghai Ctr Thyroid Dis, Shanghai 200072, Peoples R China
[4] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Pathol, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
Ultrasound; Clinicopathological; Prediction; TERT promoter; Papillary thyroid cancer; MAJOR INDICATOR; MUTATIONS; CANCER; ASSOCIATION; BRAF; RECURRENCE; NODULES; BRAF(V600E); TELOMERASE; MANAGEMENT;
D O I
10.1007/s12020-020-02214-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To investigate the value of ultrasound (US) and clinicopathological features of papillary thyroid cancer (PTC) in predicting Telomerase Reverse Transcriptase (TERT) promoter mutations. Methods Preoperative US images of 351 surgically confirmed PTCs were evaluated in terms of PTCs size and US features. The basic clinicopathological features were also retrieved. Univariate and multivariate analyses were performed to identify the risk factors for TERT promoter mutations. A scoring system was developed based on the cumulative number of risk factors. The area under the receiver operating characteristic curve (AUC) and cut-off value were calculated to evaluate the diagnostic performance of the scoring system for predicting TERT promoter mutations. Results TERT promoter mutations were found in 4.84% (17/351) of patients with PTCs. Patient age >50 years (OR: 6.244, P = 0.006), multifocality (OR: 21.071, P = 0.022), taller-than-wide shape (OR: 4.934, P = 0.029), microlobulated margin (OR: 4786, P = 0.032), and capsule contact or involvement (OR: 4.668, P = 0.030) were independent risk factors for TERT promoter mutations. TERT promoter mutations were relevant to more suspicious US and clinicopathological features than TERT promoter wild-type PTC (median, 4 vs. 1, P < 0.001). The cut-off value was 2.5 and the associated AUC was 0.908 (P < 0.001). Conclusions The probability of TERT promoter mutations increases along with the suspicious US features and clinicopathological characteristics, which may help to recognize patients who deserve a different approach, in terms of management and follow-up, in view of the worst outcome associated to this mutation.
引用
收藏
页码:349 / 357
页数:9
相关论文
共 50 条
  • [31] TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma
    Oh, Eun Ji
    Lee, Sohee
    Bae, Ja Seong
    Kim, Yourha
    Jeon, Sora
    Jung, Chan Kwon
    ENDOCRINE PATHOLOGY, 2017, 28 (01) : 49 - 53
  • [32] TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma
    Eun Ji Oh
    Sohee Lee
    Ja Seong Bae
    Yourha Kim
    Sora Jeon
    Chan Kwon Jung
    Endocrine Pathology, 2017, 28 : 49 - 53
  • [33] Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
    Jeon, Min Ji
    Kim, Won Gu
    Sim, Soyoung
    Lim, Seonhee
    Kwon, Hyemi
    Kim, Tae Yong
    Shong, Young Kee
    Kim, Won Bae
    ENDOCRINOLOGY AND METABOLISM, 2016, 31 (01) : 100 - 104
  • [34] TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma
    Sako, Ayaka
    Matsuse, Michiko
    Saenko, Vladimir
    Tanaka, Aya
    Otsubo, Ryota
    Morita, Michi
    Kuba, Sayaka
    Nishihara, Eijun
    Suzuki, Keiji
    Ogi, Tomoo
    Kawakami, Atsushi
    Mitsutake, Norisato
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (10): : e1827 - e1838
  • [35] Contribution of TERT promoter mutation status to preoperative diagnosis of thyroid carcinoma
    Bella-Cueto, M.
    Carrera, R.
    Ramos, M. D. C.
    Rodriguez, M.
    Vazquez, J. A.
    Onieva, R.
    Capel, I.
    Blazquez, C. M.
    Andreu, F. J.
    Escoda, M.
    Prenafeta, M.
    Barcons, S.
    Perez, V.
    Cano-Palomares, A.
    Guirao, F. X.
    Nebot, L.
    Gallardo, E.
    Rigla, M.
    Combalia, N.
    VIRCHOWS ARCHIV, 2019, 475 : S14 - S14
  • [36] PROGNOSTIC IMPORTANCE OF VARIOUS CLINICOPATHOLOGICAL FEATURES I PAPILLARY THYROID-CARCINOMA
    AKSLEN, LA
    MYKING, AO
    SALVESEN, H
    VARHAUG, JE
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (01) : 44 - 51
  • [37] Clinicopathological features and mutation of BRAFV600E in papillary thyroid carcinoma
    Suren, O.
    Malchinkhuu, M.
    Altangerel, Z.
    Dawaajargal, M.
    Munkhuu, P.
    Altanbayar, O.
    Baatarjalbuu, N.
    Bold-Erdene, A.
    Sharkhuu, E.
    Lkhagvadorj, S.
    Enkhbat, B.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S124 - S124
  • [38] Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis
    Yin, De-tao
    Yu, Kun
    Lu, Run-qing
    Li, Xianghua
    Xu, Jianhui
    Lei, Mengyuan
    Li, Hongqiang
    Wang, Yongfei
    Liu, Zhen
    CLINICAL ENDOCRINOLOGY, 2016, 85 (02) : 299 - 305
  • [39] MORPHOLOGIC PATTERNS AND CLINICOPATHOLOGICAL FEATURES OF PAPILLARY THYROID-CARCINOMA (PTC) IN CHILDREN
    HEFFESS, C
    ADAIR, C
    THOMPSON, L
    WENIG, B
    LABORATORY INVESTIGATION, 1995, 72 (01) : A53 - A53
  • [40] Clinicopathological features of recurrent papillary thyroid cancer
    Jian Zhu
    Xinli Wang
    Xiaoxuan Zhang
    Peifeng Li
    Haifeng Hou
    Diagnostic Pathology, 10